IP Library Granted Patent US 7,268,150
Granted Patent B2
US 7,268,150 · App. 10/492,347 · Granted Sep 11, 2007

2-cyano-4-fluoropyrrolidine derivative or its salt

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,268,150
App. No.
10/492,347
Granted
Sep 11, 2007
Kind
B2
Abstract

Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.

Claims (23)

1. A 2-cyano-4-fluoropyrrolidine compound of Formula (I):

wherein A is a group of Formula (II):

wherein R 1 -B represents methanesulfonyl, formyl or acetyl which may be substituted by a group selected from the group consisting of —OH and fluoro;

R 2 represents —H, methyl or ethyl;

or a pharmaceutically acceptable salt thereof.

2. A compound selected from the group consisting of:

4-fluoro-1-({[1-(methanesulfonyl)piperidin-4-yl]amino}acetyl)pyrrolidine-2-carbonitrile,

4-fluoro-1-({[4-methyl-1-(methanesulfonyl)piperidin-4-yl]amino}acetyl)pyrrolidine-2-carbonitrile,

4-fluoro-1-{[(1-glycoloylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile,

4-fluoro-1-{[(1-glycoloyl-4-methylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile

4-fluoro-1-{[(1-fluoroacetyl-4-methylpiperidin-4-yl)amino]acetyl}pyrrolidine -2-carbonitrile,

4-fluoro-1-{[(1-formylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile,

4-fluoro-1-{[(1-formyl-4-methylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile, and

4-fluoro-1-({[1-(morpholin-4-ylcarbonyl)piperidin-4-yl]amino}acetyl)pyrrolidine-2-carbonitrile,

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutical acceptable salt thereof of claim 1 as an active ingredient, and a pharmaceutically acceptable carrier.

4. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

(2S,4S)-4-fluoro-1-({[4-methyl-1-(methanesulfonyl)piperidin-4-yl]amino}acetyl)pyrrolidine-2-carbonitrile,

(2S,4S)-4-fluoro-1-{[(1-glycoloyl-4-methylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile,

(2S,4S)-4-fluoro-1-{[(1-fluoroacetyl-4-methylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile, and

(2S,4S)-4-fluoro-1-{[(1-formyl-4-methylpiperidin-4-yl)amino]acetyl}pyrrolidine-2-carbonitrile,

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutical acceptable salt thereof of claim 4 as an active ingredient, and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded Nov 16, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016784/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2004
From: HAYAKAWA, MASAHIKO; NEGORO, KENJI; MIYAMOTO, SATOSHI; SUZUKI, TAKAYUKI; MARUYAMA, TATSUYA; NAKANO, RYOSUKE
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 016297/0727 →